Research study Program year 2020 Source: CMS Open Payments

A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosin

ClinicalTrials.gov NCT03215277

Research payments

$38,979

3 payments

Through program year 2020, $38,979 in research payments was reported against A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosin, across 3 payments, paid by Ucb SA.

Paid by: Ucb SA
ClinicalTrials.gov: NCT03215277

By program year

1 row

Year	Kind	Amount	Payments
2020	Research	$38,979	3

Breakdown

Who paid Research payments · program year 2020

Ucb SA $38,979 3 payments

Who received the money Research payments · program year 2020

International Eye Associates P.A. Organisation paid for research $32,029 2 payments
McIlwain Medical Group, PA Organisation paid for research $6,950 1 payment

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

2 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.